Memphasys Ltd
Memphasys Limited is an Australia-based reproductive biotechnology company.
The business
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing medical devices, diagnostics, and media with application to assisted reproductive technology (ART) in humans and animals. The Company's product pipeline includes Felix, RoXsta, and AI-Port. Its advanced product, the Felix System, is a patented automated device for quickly and gently separating sperm from a semen sample for use in ART procedures. The Felix device consists of two main components: a console, which supplies electrical power, and a sterile disposable cartridge for sperm isolation and selection. RoXsta is an in-vitro diagnostic device that assesses semen and other bodily fluids for oxidative stress load. RoXsta also has an application as part of a suite of products that can support the animal industry. AI-Port has been developed for the purpose of maintaining the viability of livestock semen for up to seven days at a temperature range of 22 - 25 degrees Celsius.
Small Caps Research
No research on Memphasys Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise MEM based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Memphasys Signs Agreement to Distribute Felix Fertility Device Across Middle East and North Africa
Memphasys (ASX: MEM) has granted Qatar-based company International Technical Legacy (ITL) exclusive commercial and distribution rights to its innovative Felix male fertility sperm preparation system. The five-year deal applies to approximately 353 clinics across 15 countries across the Middle East and North Africa, which perform a cumulative 140,000 in vitro fertilisation (IVF) cycles per year. […]
Memphasys pilot study confirms RoXsta’s potential as high-throughput antioxidant diagnostic tool
A pilot study has shown that Memphasys’ (ASX: MEM) RoXsta Mega Cell high-throughput assay device can conduct large-scale, simultaneous antioxidant assays within a lab setting. The study demonstrated that the next-generation analytical platform was able to process 96 samples in less than one hour, returning highly accurate antioxidant readings for individuals requiring antioxidant therapy. The […]
Memphasys achieves key milestone with clinical validation of Felix fertility device
Memphasys (ASX: MEM) has published positive data from a pivotal clinical trial of its Felix electrophoresis-based sperm separation device for use in assisted reproduction. The trial validated the ability of the Felix device to meet and exceed industry benchmarks and found it to be non-inferior to the “swim-up” technique but statistically superior to DGC (density-gradient […]
Peer review confirms Memphasys’ Felix system superior to conventional sperm preparation for human IVF
In vitro results from study findings on the Felix system developed by reproductive biotechnology company Memphasys (ASX: MEM) have demonstrated it can outperform conventional sperm preparation methods for human IVF (in vitro fertilisation) procedures. Two articles by key opinion leaders (KOL) evaluating the Felix system device have found the system is superior to the density […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.